Morgan Stanley’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.37B | Buy |
8,726,827
+199,790
| +2% | +$30M | 0.07% | 240 |
|
|
2026
Q1 | $1.3B | Sell |
8,527,037
-349,869
| -4% | -$53.6M | 0.08% | 226 |
|
|
2025
Q4 | $1.22B | Buy |
8,876,906
+1,148,033
| +15% | +$150M | 0.07% | 239 |
|
|
2025
Q3 | $991M | Buy |
7,728,873
+169,385
| +2% | +$20.7M | 0.06% | 288 |
|
|
2025
Q2 | $915M | Buy |
7,559,488
+503,577
| +7% | +$56.8M | 0.06% | 299 |
|
|
2025
Q1 | $787M | Buy |
7,055,911
+186,756
| +3% | +$19.9M | 0.06% | 323 |
|
|
2024
Q4 | $668M | Sell |
6,869,155
-115,717
| -2% | -$12.3M | 0.05% | 376 |
|
|
2024
Q3 | $803M | Sell |
6,984,872
-431,807
| -6% | -$49M | 0.06% | 304 |
|
|
2024
Q2 | $790M | Buy |
7,416,679
+158,298
| +2% | +$15.9M | 0.06% | 281 |
|
|
2024
Q1 | $702M | Buy |
7,258,381
+166,128
| +2% | +$17M | 0.06% | 314 |
|
|
2023
Q4 | $716M | Buy |
7,092,253
+114,420
| +2% | +$11M | 0.06% | 281 |
|
|
2023
Q3 | $711M | Sell |
6,977,833
-287,598
| -4% | -$29.2M | 0.07% | 259 |
|
|
2023
Q2 | $733M | Buy |
7,265,431
+650,965
| +10% | +$65.1M | 0.07% | 255 |
|
|
2023
Q1 | $609M | Buy |
6,614,466
+126,270
| +2% | +$11M | 0.07% | 290 |
|
|
2022
Q4 | $589M | Buy |
6,488,196
+377,693
| +6% | +$31.8M | 0.07% | 301 |
|
|
2022
Q3 | $464M | Sell |
6,110,503
-288,283
| -5% | -$23.9M | 0.06% | 292 |
|
|
2022
Q2 | $541M | Buy |
6,398,786
+3,134,810
| +96% | +$275M | 0.07% | 265 |
|
|
2022
Q1 | $286M | Sell |
3,263,976
-219,673
| -6% | -$19M | 0.04% | 418 |
|
|
2021
Q4 | $305M | Buy |
3,483,649
+267,670
| +8% | +$22.2M | 0.04% | 424 |
|
|
2021
Q3 | $263M | Buy |
3,215,979
+256,018
| +9% | +$23M | 0.04% | 445 |
|
|
2021
Q2 | $270M | Buy |
2,959,961
+119,862
| +4% | +$10.7M | 0.04% | 438 |
|
|
2021
Q1 | $243M | Buy |
2,840,099
+31,106
| +1% | +$2.79M | 0.04% | 428 |
|
|
2020
Q4 | $265M | Buy |
2,808,993
+263,445
| +10% | +$23M | 0.04% | 380 |
|
|
2020
Q3 | $221M | Sell |
2,545,548
-143,207
| -5% | -$12.4M | 0.04% | 355 |
|
|
2020
Q2 | $235M | Sell |
2,688,755
-1,067,159
| -28% | -$92.1M | 0.05% | 307 |
|
|
2020
Q1 | $310M | Buy |
3,755,914
+965,770
| +35% | +$86.2M | 0.08% | 208 |
|
|
2019
Q4 | $264M | Buy |
2,790,144
+357,703
| +15% | +$32.1M | 0.06% | 301 |
|
|
2019
Q3 | $211M | Buy |
2,432,441
+23,073
| +1% | +$2.07M | 0.06% | 334 |
|
|
2019
Q2 | $220M | Sell |
2,409,368
-1,031,665
| -30% | -$87.3M | 0.06% | 320 |
|
|
2019
Q1 | $296M | Buy |
3,441,033
+221,164
| +7% | +$17.8M | 0.08% | 255 |
|
|
2018
Q4 | $248M | Sell |
3,219,869
-59,614
| -2% | -$4.64M | 0.07% | 274 |
|
|
2018
Q3 | $253M | Buy |
3,279,483
+38,721
| +1% | +$2.86M | 0.06% | 301 |
|
|
2018
Q2 | $219M | Sell |
3,240,762
-20,995
| -0.6% | -$1.45M | 0.06% | 319 |
|
|
2018
Q1 | $236M | Buy |
3,261,757
+331,447
| +11% | +$25.2M | 0.07% | 292 |
|
|
2017
Q4 | $220M | Buy |
2,930,310
+335,687
| +13% | +$25.3M | 0.06% | 326 |
|
|
2017
Q3 | $200M | Buy |
2,594,623
+552,826
| +27% | +$41.8M | 0.06% | 313 |
|
|
2017
Q2 | $153M | Sell |
2,041,797
-116,428
| -5% | -$8.25M | 0.05% | 404 |
|
|
2017
Q1 | $144M | Buy |
2,158,225
+138,862
| +7% | +$9.25M | 0.04% | 418 |
|
|
2016
Q4 | $132M | Sell |
2,019,363
-30,189
| -1% | -$1.96M | 0.04% | 440 |
|
|
2016
Q3 | $145M | Buy |
2,049,552
+64,749
| +3% | +$4.72M | 0.05% | 408 |
|
|
2016
Q2 | $147M | Sell |
1,984,803
-23,852
| -1% | -$1.65M | 0.05% | 390 |
|
|
2016
Q1 | $130M | Sell |
2,008,655
-28,854
| -1% | -$1.96M | 0.05% | 393 |
|
|
2015
Q4 | $157M | Sell |
2,037,509
-305,823
| -13% | -$24.3M | 0.06% | 349 |
|
|
2015
Q3 | $193M | Sell |
2,343,332
-145,033
| -6% | -$12.9M | 0.07% | 293 |
|
|
2015
Q2 | $219M | Buy |
2,488,365
+369,382
| +17% | +$33.9M | 0.08% | 291 |
|
|
2015
Q1 | $187M | Sell |
2,118,983
-196,153
| -8% | -$17.4M | 0.07% | 315 |
|
|
2014
Q4 | $192M | Buy |
2,315,136
+247,162
| +12% | +$20.5M | 0.07% | 300 |
|
|
2014
Q3 | $174M | Buy |
2,067,974
+167,897
| +9% | +$13.6M | 0.07% | 322 |
|
|
2014
Q2 | $154M | Sell |
1,900,077
-146,127
| -7% | -$11.5M | 0.06% | 358 |
|
|
2014
Q1 | $156M | Sell |
2,046,204
-367,086
| -15% | -$26.7M | 0.07% | 331 |
|
|
2013
Q4 | $174M | Buy |
2,413,290
+265,015
| +12% | +$18.4M | 0.07% | 299 |
|
|
2013
Q3 | $148M | Sell |
2,148,275
-2,151,905
| -50% | -$142M | 0.07% | 328 |
|
|
2013
Q2 | $272M | Buy |
+4,300,180
| New | +$280M | 0.14% | 182 |
|
Other funds holding NVS
Morgan Stanley's NVS Position: Q2 2026 in Review
Morgan Stanley increased its Novartis (NVS) stake by 2.3% in Q2 2026, buying an estimated $30M and bringing the position to 8,726,827 shares worth $1.37B. The position accounts for 0.07% of the portfolio, ranked #240.
Morgan Stanley first reported a position in NVS in Q2 2013 and has held it in 53 quarters since. 1,618 funds tracked by Wall St. Rank hold NVS as of Q2 2026.
- Morgan Stanley held 8,726,827 shares of Novartis worth $1.37B as of Q2 2026.
- Morgan Stanley bought 199,790 Novartis shares in Q2 2026, an estimated $30M.
- Novartis made up 0.07% of Morgan Stanley's portfolio in Q2 2026, its #240 holding.
- Morgan Stanley first reported a position in Novartis in Q2 2013 and has held it in 53 quarters since.
- 1,618 funds tracked by Wall St. Rank held Novartis as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.